Drugs / BG-68501
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06257264 | Mar 2024 → Aug 2026 overdue | endometrial cancer, gastric cancer, gastroesophageal cancer, hormone receptor-positive breast cancer +5 | BeiGene | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-68501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06257264 ↗ |
| Action | Inhibit | “a Selective CDK2 Inhibitor” NCT06257264 ↗ |
| Route | Oral | “Planned doses administered orally.” NCT06257264 ↗ |
| Target | CDK2 | “BG-68501, a Selective CDK2 Inhibitor” NCT06257264 ↗ |